Covidien is now Medtronic Minimally Invasive Therapies

LEARN MORE

Medtronic Center of Innovation Korea

In the last week of August, the second Covidien Center of Innovation (CCI) opened its doors, ushering in a new era of medical research, development, training and education for healthcare professionals in Korea.

The 2,840 m2 facility is located in Osong and represents a multi-million dollar investment by Covidien. Recently, the Korean Surgical Society passed a regulation requiring in-country training of surgeons who plan to practice in Korea. The CCI Korea was developed to make access to training easy for Korean surgeons, so Covidien could continue to help advance physician capabilities and partner closely with practitioners to uncover opportunities for locally tailored solutions.

"It is our responsibility and honor to help advance physician capabilities and uncover opportunities for locally tailored solutions to increase global access to the best patient care,” said Brian King, President, Emerging Markets, at the opening. “Korea is a key market in our global strategy, and this investment is a reflection of our commitment to partnering with Korean healthcare professionals.”

Also in attendance at the opening were officials from Korea's Ministry of Food and Drugs Safety, Provincial Government of Chungcheongbuk-do, Health Insurance Review and Assessment Service and the U.S. Embassy

“This significant investment will give clinicians in Korea and the region important access to medical training and create an opportunity to further participate in the development of medical technologies for Korea. We hope Covidien’s investment will encourage other healthcare companies to further invest in Osong and support our vision to make Korea a global leader in life sciences and medicine,” said Jin-ho Wang, Director General of the National Institute of Food Drug Safety Evaluation.

Access to the latest technology, raising the standard of capabilities

CCI Korea features 11 surgical tables, an Intensive Care Unit lab and vascular therapy labs outfitted with the latest medical products and devices and an auditorium. It also boasts innovative technology including a human patient simulator, the first available at a medical training facility in the country.

Much of the Covidien product portfolio will be available at the facility, which will primarily focus on the products used in minimally invasive surgery procedures. Visitors to the site will learn about the efficacy of our products and procedures and will provide feedback that will help Covidien design products and solutions specific to the Korean market.

Peter Kim, Managing Director of Covidien Korea said, “The attention to and expectation of medical technology have risen in Korea, especially due to the aging population, but systematic medical training opportunities as well as qualified facilities with the latest medical devices have been very limited.”

“With the opening of CCI Korea, Covidien will help further raise the standard of medical capabilities in Korea, while boosting our collaboration with academic institutions,” continued Peter.

In fact, earlier this year Covidien signed agreements that will bring healthcare professionals belonging to the Korean Surgical Society and the Korean Society for Thoracic & Cardiovascular Surgery to CCI Korea as part of their mandatory certification programs.

More CCI facilities to come

The Osong facility is Covidien's second Center of Innovation. The first CCI in Shanghai, China trained more than 3,300 healthcare professionals in 2012 alone.